Free Trial
→ Trump wipes out trillions overnight… (From Porter & Company) (Ad) Buy BCRX Stock  Free BCRX Stock Alerts

BioCryst Pharmaceuticals (BCRX) Financials

BioCryst Pharmaceuticals logo
$11.05 +2.12 (+23.75%)
Closing price 03:59 PM Eastern
Extended Trading
$11.03 -0.02 (-0.19%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for BioCryst Pharmaceuticals

Annual Income Statements for BioCryst Pharmaceuticals

This table shows BioCryst Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -45 -43 -55 -66 -101 -109 -183 -184 -247 -225 -89
Consolidated Net Income / (Loss)		 -45 -43 -55 -66 -101 -109 -183 -184 -247 -227 -89
Net Income / (Loss) Continuing Operations		 -45 -43 -55 -66 -101 -109 -183 -184 -247 -227 -89
Total Pre-Tax Income 		-45 -43 -55 -66 -101 -109 -183 -182 -244 -226 -87
Total Operating Income		 -46 -39 -49 -57 -94 -99 -175 -178 -148 -104 -2.54
Total Gross Profit		 14 47 24 24 21 45 16 150 264 327 438
Total Revenue		 14 48 26 25 21 49 18 157 271 331 451
Operating Revenue		 14 48 26 25 21 49 18 157 271 331 451
Total Cost of Revenue		 0.00 1.37 2.30 1.14 0.00 3.73 1.55 7.23 6.41 4.48 12
Operating Cost of Revenue		 0.00 1.37 2.30 1.14 0.00 3.73 1.55 7.23 6.41 4.48 12
Total Operating Expenses		 59 86 73 81 115 145 191 328 413 431 441
Selling, General & Admin Expense		 7.46 13 11 14 30 37 68 119 159 214 266
Research & Development Expense		 52 73 61 67 85 107 123 209 253 217 175
Other Operating Expenses / (Income)		 0.12 0.53 0.40 0.56 0.47 0.38 0.13 0.04 0.19 0.18 0.22
Total Other Income / (Expense), net		 0.58 -3.58 -6.54 -8.37 -7.03 -9.44 -8.06 -4.09 -96 -123 -84
Interest Expense		 5.00 5.20 6.49 8.57 6.92 9.96 7.09 3.46 99 137 99
Interest & Investment Income		 5.58 1.63 -0.05 0.19 - 0.52 -0.97 -0.63 3.14 15 14
Income Tax Expense		 - - - - - 0.00 0.00 2.25 2.73 0.31 1.93
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.13 0.08 -0.19 0.23 - -0.34 0.04 -0.17 -0.89 -0.18 0.78
Basic Earnings per Share		 ($0.68) ($0.59) ($0.75) ($0.78) ($0.98) ($940.00) ($1.09) ($1.03) ($1.33) ($1.18) ($0.43)
Weighted Average Basic Shares Outstanding		 66.77M 73M 73.30M 84.60M 103.40M 154.19M 167.27M 179.12M 185.91M 192.20M 206.70M
Diluted Earnings per Share		 ($0.68) ($0.59) ($0.75) ($0.78) ($0.98) ($940.00) ($1.09) ($1.03) ($1.33) ($1.18) ($0.43)
Weighted Average Diluted Shares Outstanding		 66.77M 72.90M 73.70M 84.45M 103.19M 115.60M 167.27M 179.12M 185.91M 192.20M 206.70M
Weighted Average Basic & Diluted Shares Outstanding		 66.77M 73M 73.30M 84.60M 103.40M 154.19M 177.18M 184.66M 188.45M 206.15M 208.96M

Quarterly Income Statements for BioCryst Pharmaceuticals

This table shows BioCryst Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -43 -71 -53 -75 -36 -61 -36 -13 -12 -28
Consolidated Net Income / (Loss)		 -43 -72 -53 -75 -36 -62 -35 -13 -14 -27
Net Income / (Loss) Continuing Operations		 -43 -72 -53 -75 -36 -62 -35 -13 -14 -27
Total Pre-Tax Income 		-41 -71 -53 -75 -36 -63 -35 -13 -13 -26
Total Operating Income		 -17 -46 -28 -21 -12 -43 -14 8.76 7.69 -4.51
Total Gross Profit		 72 77 68 82 86 92 91 108 114 125
Total Revenue		 76 80 69 82 87 93 93 109 117 132
Operating Revenue		 76 80 69 82 87 93 93 109 117 132
Total Cost of Revenue		 3.54 2.38 0.93 0.89 1.10 1.56 1.27 1.70 3.21 6.09
Operating Cost of Revenue		 3.54 2.38 0.93 0.89 1.10 1.56 1.27 1.70 3.21 6.09
Total Operating Expenses		 90 123 96 102 98 135 106 99 106 130
Selling, General & Admin Expense		 37 50 48 51 51 64 59 61 65 80
Research & Development Expense		 53 73 48 51 47 70 46 38 41 49
Other Operating Expenses / (Income)		 0.07 0.11 0.01 0.06 0.04 0.08 0.13 0.04 0.02 0.04
Total Other Income / (Expense), net		 -24 -25 -24 -54 -24 -20 -21 -21 -21 -21
Interest Expense		 25 26 27 58 27 25 25 25 25 24
Interest & Investment Income		 1.22 1.30 3.15 4.05 3.45 4.09 3.98 3.47 3.69 2.97
Income Tax Expense		 1.52 0.08 0.67 0.74 0.33 -1.43 0.37 0.17 0.59 0.80
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.11 -1.17 -0.56 -0.11 -0.11 0.59 0.57 0.21 -1.74 1.73
Basic Earnings per Share		 ($0.23) ($0.38) ($0.28) ($0.40) ($0.19) ($0.31) ($0.17) ($0.06) ($0.07) ($0.13)
Weighted Average Basic Shares Outstanding		 186.18M 185.91M 188.51M 189.12M 189.64M 192.20M 206.06M 206.43M 206.91M 206.70M
Diluted Earnings per Share		 ($0.23) ($0.38) ($0.28) ($0.40) ($0.19) ($0.31) ($0.17) ($0.06) ($0.07) ($0.13)
Weighted Average Diluted Shares Outstanding		 186.18M 185.91M 188.51M 189.12M 189.64M 192.20M 206.06M 206.43M 206.91M 206.70M
Weighted Average Basic & Diluted Shares Outstanding		 186.42M 188.45M 188.93M 189.49M 204.81M 206.15M 206.38M 206.89M 207.13M 208.96M

Annual Cash Flow Statements for BioCryst Pharmaceuticals

This table details how cash moves in and out of BioCryst Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 33 -26 -6.86 30 -25 87 159 233 -201 -194 -6.12
Net Cash From Operating Activities		 -39 -13 -53 -41 -93 -90 -135 -142 -162 -95 -52
Net Cash From Continuing Operating Activities		 -39 -13 -53 -41 -93 -90 -135 -142 -162 -95 -52
Net Income / (Loss) Continuing Operations		 -45 -43 -55 -66 -101 -109 -183 -184 -247 -227 -89
Consolidated Net Income / (Loss)		 -45 -43 -55 -66 -101 -109 -183 -184 -247 -227 -89
Depreciation Expense		 0.18 0.18 0.48 0.70 0.77 0.72 0.75 0.78 1.44 1.66 1.25
Amortization Expense		 0.59 1.01 1.08 1.03 1.00 1.40 3.45 54 97 76 56
Non-Cash Adjustments To Reconcile Net Income		 10 9.71 8.50 13 9.40 18 16 -21 46 87 67
Changes in Operating Assets and Liabilities, net		 -4.33 19 -8.36 10 -2.48 -0.53 28 8.12 -59 -32 -87
Net Cash From Investing Activities		 -40 -18 23 -65 4.77 78 -6.86 16 -128 -131 53
Net Cash From Continuing Investing Activities		 -40 -18 23 -65 4.77 78 -6.86 16 -128 -131 53
Purchase of Property, Plant & Equipment		 -0.11 -5.12 -5.28 -0.33 -0.37 -0.34 -0.51 -2.39 -1.35 -2.17 -1.12
Purchase of Investments		 -74 -54 -14 -108 -63 -3.02 -50 -10 -244 -514 -267
Sale and/or Maturity of Investments		 34 42 43 43 68 81 43 28 117 385 320
Net Cash From Financing Activities		 112 5.48 23 136 63 99 301 360 88 32 -5.76
Net Cash From Continuing Financing Activities		 112 5.48 23 136 63 99 301 360 88 32 -5.76
Repayment of Debt		 0.00 0.00 0.00 0.00 -4.03 0.00 -52 0.00 0.00 -273 0.00
Issuance of Debt		 - - 23 0.00 10 19 120 0.00 73 300 0.00
Issuance of Common Equity		 107 0.00 0.00 134 53 78 108 66 15 8.34 3.44
Other Financing Activities, net		 5.31 5.48 0.65 1.70 2.78 1.24 125 294 0.19 -3.00 -9.21
Effect of Exchange Rate Changes		 - - - - - 0.00 - 0.07 0.57 0.36 -0.94
Cash Interest Paid		 - - - - - - - 0.90 0.00 22 30
Cash Income Taxes Paid		 - - - - - - - 0.12 3.54 1.43 1.60

Quarterly Cash Flow Statements for BioCryst Pharmaceuticals

This table details how cash moves in and out of BioCryst Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -26 58 -150 -8.81 4.70 -40 -26 -5.93 19 7.26
Net Cash From Operating Activities		 -32 -24 -48 -19 -20 -8.92 -54 -1.37 8.25 -5.21
Net Cash From Continuing Operating Activities		 -32 -24 -48 -19 -20 -8.92 -54 -1.37 8.25 -5.21
Net Income / (Loss) Continuing Operations		 -43 -72 -53 -75 -36 -62 -35 -13 -14 -27
Consolidated Net Income / (Loss)		 -43 -72 -53 -75 -36 -62 -35 -13 -14 -27
Depreciation Expense		 0.39 0.40 0.41 0.41 0.42 0.42 0.31 0.32 0.31 0.31
Amortization Expense		 18 43 19 21 20 16 16 16 12 11
Non-Cash Adjustments To Reconcile Net Income		 9.95 16 14 42 12 18 14 13 19 21
Changes in Operating Assets and Liabilities, net		 -18 -12 -28 -6.64 -16 18 -49 -18 -9.13 -11
Net Cash From Investing Activities		 -70 77 -107 -19 23 -28 29 -2.45 8.49 18
Net Cash From Continuing Investing Activities		 -70 77 -107 -19 23 -28 29 -2.45 8.49 18
Purchase of Property, Plant & Equipment		 -0.18 -0.53 -0.16 -0.47 -0.99 -0.55 -0.24 -0.16 -0.06 -0.68
Purchase of Investments		 -105 - -149 -85 -124 -157 -88 -112 -27 -40
Sale and/or Maturity of Investments		 36 78 42 66 148 129 117 110 35 58
Net Cash From Financing Activities		 76 4.20 5.08 29 1.23 -3.17 -1.05 -1.97 1.27 -4.02
Net Cash From Continuing Financing Activities		 76 4.20 5.08 29 1.23 -3.17 -1.05 -1.97 1.27 -4.02
Issuance of Common Equity		 - - 5.08 1.75 1.48 0.04 1.68 0.26 2.09 -0.59
Other Financing Activities, net		 3.25 -11 0.00 0.21 0.01 -3.21 -2.73 -2.23 -0.81 -3.44
Effect of Exchange Rate Changes		 -0.01 0.33 -0.10 -0.32 0.25 0.52 -0.34 -0.14 0.85 -1.30
Cash Interest Paid		 - - 7.14 5.16 4.85 4.99 4.99 5.05 10 10
Cash Income Taxes Paid		 - - 0.14 0.98 0.32 -0.01 0.19 0.68 0.36 0.38

Annual Balance Sheets for BioCryst Pharmaceuticals

This table presents BioCryst Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 137 122 90 178 147 175 335 588 550 517 490
Total Current Assets		 89 64 67 125 114 164 324 566 517 496 422
Cash & Equivalents		 55 29 22 50 27 114 272 504 305 111 105
Restricted Cash		 0.15 1.61 1.55 3.29 1.54 1.55 2.22 3.35 1.47 1.80 0.21
Short-Term Investments		 18 23 33 64 78 22 28 3.21 120 278 216
Accounts Receivable		 9.49 6.24 8.77 6.12 4.29 22 8.65 29 51 57 79
Inventories, net		 0.68 1.61 0.50 0.00 1.65 0.00 7.04 16 28 29 8.09
Prepaid Expenses		 6.17 2.67 1.44 1.38 2.40 4.42 5.53 9.99 13 20 14
Plant, Property, & Equipment, net		 0.21 5.15 9.92 9.55 - 7.35 7.11 8.71 8.62 7.91 7.78
Total Noncurrent Assets		 47 53 13 43 - 3.59 3.80 13 25 13 61
Long-Term Investments		 41 48 8.93 41 22 - 0.00 6.83 18 0.00 20
Other Noncurrent Operating Assets		 6.21 5.73 4.01 2.03 0.98 3.59 3.80 6.47 6.81 13 40
Total Liabilities & Shareholders' Equity		 137 122 90 178 147 175 335 588 550 517 490
Total Liabilities		 61 75 88 94 - 137 354 695 845 972 966
Total Current Liabilities		 57 62 54 75 69 92 106 104 106 150 160
Accounts Payable		 2.85 9.31 4.27 6.34 7.77 14 19 28 14 21 12
Accrued Expenses		 11 16 11 13 16 21 34 73 88 103 113
Other Current Liabilities		 - - - - - 1.38 1.18 1.82 2.37 26 35
Total Noncurrent Liabilities		 3.95 12 34 20 - 45 248 591 739 823 806
Long-Term Debt		 - 0.00 23 17 25 41 120 136 232 303 315
Other Noncurrent Operating Liabilities		 - - - - 2.70 0.00 129 455 507 519 491
Total Equity & Noncontrolling Interests		 76 48 1.58 84 - 38 -19 -107 -295 -456 -476
Total Preferred & Common Equity		 76 48 1.58 84 - 38 -19 -107 -295 -456 -476
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 76 48 1.58 84 - 38 -19 -107 -295 -456 -476
Common Stock		 544 559 568 716 782 879 1,004 1,100 1,160 1,224 1,293
Retained Earnings		 -468 -511 -566 -632 -732 -841 -1,023 -1,208 -1,455 -1,681 -1,770
Accumulated Other Comprehensive Income / (Loss)		 -0.13 -0.21 -0.01 -0.24 -0.30 0.04 0.00 0.18 0.03 1.34 0.92

Quarterly Balance Sheets for BioCryst Pharmaceuticals

This table presents BioCryst Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 559 510 530 523 468 472 491
Total Current Assets		 509 491 511 502 447 363 427
Cash & Equivalents		 247 155 146 151 84 78 97
Restricted Cash		 1.44 1.46 1.57 1.58 1.80 1.80 0.81
Short-Term Investments		 180 243 264 247 252 194 233
Accounts Receivable		 43 49 58 54 61 69 72
Inventories, net		 27 27 27 30 30 4.45 7.56
Prepaid Expenses		 11 15 14 20 18 16 16
Plant, Property, & Equipment, net		 8.46 8.38 8.44 9.00 7.83 7.66 7.42
Total Noncurrent Assets		 41 10 10 11 13 101 57
Long-Term Investments		 34 3.43 3.45 0.00 - 64 19
Other Noncurrent Operating Assets		 6.80 7.05 6.95 11 13 37 37
Total Liabilities & Shareholders' Equity		 559 510 530 523 468 472 491
Total Liabilities		 801 838 919 934 944 948 960
Total Current Liabilities		 82 85 93 91 120 129 154
Accounts Payable		 8.62 6.25 14 11 12 7.79 13
Accrued Expenses		 69 75 75 77 79 90 104
Other Current Liabilities		 2.20 2.49 2.53 2.28 29 32 36
Total Noncurrent Liabilities		 720 753 825 843 824 819 806
Long-Term Debt		 224 233 293 298 308 314 314
Other Noncurrent Operating Liabilities		 490 514 526 535 516 505 492
Total Equity & Noncontrolling Interests		 -243 -328 -389 -411 -476 -476 -469
Total Preferred & Common Equity		 -243 -328 -389 -411 -476 -476 -469
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -243 -328 -389 -411 -476 -476 -469
Common Stock		 1,141 1,179 1,194 1,208 1,240 1,253 1,272
Retained Earnings		 -1,383 -1,508 -1,583 -1,619 -1,717 -1,729 -1,743
Accumulated Other Comprehensive Income / (Loss)		 -0.10 0.59 0.69 0.80 0.77 0.56 2.29

Annual Metrics and Ratios for BioCryst Pharmaceuticals

This table displays calculated financial ratios and metrics derived from BioCryst Pharmaceuticals' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -21.48% 254.62% -45.39% -4.43% -18.00% 136.45% -63.53% 782.38% 72.31% 22.37% 36.00%
EBITDA Growth		 -349.00% 15.00% -22.97% -18.35% -66.26% -5.16% -75.23% 28.04% 59.38% 46.82% 306.82%
EBIT Growth		 -364.10% 13.82% -23.23% -18.11% -64.30% -5.44% -75.71% -1.70% 16.48% 30.13% 97.55%
NOPAT Growth		 -284.87% 13.82% -23.23% -18.11% -64.11% -5.56% -75.71% -1.70% 16.48% 30.13% 97.55%
Net Income Growth		 -50.09% 4.80% -28.19% -19.29% -53.92% -7.55% -67.88% -0.68% -34.26% 8.33% 60.77%
EPS Growth		 0.00% 13.24% -27.12% -4.00% -25.64% -95,818.37% 99.88% 5.50% -29.13% 11.28% 63.56%
Operating Cash Flow Growth		 -45.31% 65.98% -307.43% 23.01% -124.98% 3.22% -50.82% -5.22% -13.85% 41.22% 45.32%
Free Cash Flow Firm Growth		 -289.85% 63.47% -258.63% 33.97% -102.67% -15.71% 134.99% 698.80% -140.10% 57.62% -16.73%
Invested Capital Growth		 70.50% -582.77% 94.88% -911.33% 1.94% 83.66% -11,085.43% -224.82% -3.71% -7.15% 7.48%
Revenue Q/Q Growth		 0.00% -1.72% 19.94% -16.82% -5.32% 312.49% -66.72% 37.83% 13.58% 4.36% 9.24%
EBITDA Q/Q Growth		 -483.61% -5.73% 16.30% -20.99% -8.91% 20.71% -42.04% 11.32% 38.49% -677.54% 154.10%
EBIT Q/Q Growth		 -512.39% -5.45% 15.63% -20.26% -8.65% 20.19% -42.70% 0.13% 3.80% 3.39% 93.75%
NOPAT Q/Q Growth		 -512.39% -5.45% 15.63% -20.26% -8.52% 20.19% -42.70% 0.13% 3.80% 3.39% 93.75%
Net Income Q/Q Growth		 -16.03% -17.68% 19.82% -29.64% -8.45% 18.56% -46.32% 18.84% -27.81% 4.15% 28.22%
EPS Q/Q Growth		 -11.48% -15.69% 19.35% -21.88% -5.38% -77,585.95% 99.92% -100.21% -26.67% 5.60% 29.51%
Operating Cash Flow Q/Q Growth		 -32.13% -7.70% 14.38% -12.79% -17.02% 13.13% -31.14% 6.62% 5.05% 13.56% 6.65%
Free Cash Flow Firm Q/Q Growth		 -484.81% -193.83% 43.11% 3.07% -13.58% -13.38% 127.97% 1,088.45% -141.00% 24.92% -61.84%
Invested Capital Q/Q Growth		 74.50% 67.69% 77.38% -144.94% -37.46% 94.77% -855.62% -208.71% -6.60% -8.14% 0.40%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 99.99% 97.17% 91.28% 95.47% 100.00% 92.37% 91.30% 95.40% 97.63% 98.65% 97.28%
EBITDA Margin		 -330.72% -79.27% -178.51% -221.05% -448.18% -199.32% -957.57% -78.09% -18.41% -8.00% 12.17%
Operating Margin		 -336.35% -81.74% -184.45% -227.95% -456.20% -203.66% -981.12% -113.08% -54.81% -31.29% -0.56%
EBIT Margin		 -336.35% -81.74% -184.45% -227.95% -456.73% -203.66% -981.12% -113.08% -54.81% -31.29% -0.56%
Profit (Net Income) Margin		 -332.08% -89.15% -209.25% -261.18% -490.25% -222.99% -1,026.35% -117.11% -91.25% -68.36% -19.72%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 101.24% 101.12% 100.14% 102.22%
Interest Burden Percent		 98.73% 109.06% 113.45% 114.58% 107.34% 109.49% 104.61% 102.30% 164.64% 218.14% 3,419.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -121.30% -69.75% -223.70% -154.16% -152.26% -248.94% -1,925.37% 291.59% 123.07% 60.40% 19.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -49.29% -30.43% -45.81% -42.83% -58.03% -61.75% -68.53% -38.51% -26.08% -19.44% -0.50%
Return on Assets (ROA)		 -48.66% -33.19% -51.97% -49.07% -62.29% -67.61% -71.69% -39.89% -43.42% -42.46% -17.65%
Return on Common Equity (ROCE)		 -121.30% -69.75% -223.70% -154.16% -152.26% -248.94% -1,925.37% 291.59% 123.07% 60.40% 19.08%
Return on Equity Simple (ROE_SIMPLE)		 -59.75% -90.14% -3,494.55% -78.53% -205.65% -284.68% 949.09% 172.04% 83.88% 49.73% 18.68%
Net Operating Profit after Tax (NOPAT)		 -32 -28 -34 -40 -66 -70 -122 -124 -104 -73 -1.78
NOPAT Margin		 -235.45% -57.22% -129.11% -159.56% -319.34% -142.56% -686.78% -79.15% -38.37% -21.91% -0.40%
Net Nonoperating Expense Percent (NNEP)		 -30.97% -21.71% -63.67% -54.13% -47.18% -80.93% -70.83% -23.26% -48.23% -102.70% -152.71%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 165.00% 47.67% 1.11%
Cost of Revenue to Revenue		 0.01% 2.83% 8.72% 4.53% 0.00% 7.63% 8.70% 4.60% 2.37% 1.35% 2.72%
SG&A Expenses to Revenue		 54.83% 27.04% 42.70% 55.32% 142.90% 76.01% 381.37% 75.60% 58.85% 64.54% 59.05%
R&D to Revenue		 380.63% 150.77% 231.50% 265.87% 411.02% 219.24% 690.34% 132.85% 93.53% 65.35% 38.75%
Operating Expenses to Revenue		 436.35% 178.90% 275.73% 323.41% 556.20% 296.03% 1,072.42% 208.48% 152.44% 129.94% 97.84%
Earnings before Interest and Taxes (EBIT)		 -46 -39 -49 -57 -94 -99 -175 -178 -148 -104 -2.54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -38 -47 -56 -93 -97 -171 -123 -50 -27 55
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 15.86 295.87 5.77 17.97 9.96 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 15.86 295.87 5.77 17.97 9.96 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 15.68 17.72 19.18 42.84 7.80 73.85 15.86 7.90 3.70 3.46
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 14.22 17.28 15.04 39.49 6.69 65.27 13.43 7.12 3.44 3.40
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 27.92
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 43.43 9.87 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.40 0.63 34.05 0.65 1.20 2.18 -7.77 -1.27 -0.79 -0.67 -0.66
Long-Term Debt to Equity		 0.00 0.05 16.15 0.23 0.52 1.17 -6.22 -1.27 -0.79 -0.67 -0.66
Financial Leverage		 -1.14 -1.15 -1.35 -1.11 -1.13 -1.11 -8.99 4.06 1.48 0.40 0.12
Leverage Ratio		 2.49 2.10 4.30 3.14 2.44 3.68 26.86 -7.31 -2.83 -1.42 -1.08
Compound Leverage Factor		 2.46 2.29 4.88 3.60 2.62 4.03 28.09 -7.48 -4.67 -3.10 -36.98
Debt to Total Capital		 28.40% 38.74% 97.15% 39.51% 54.54% 68.52% 114.76% 467.70% -367.81% -199.11% -195.49%
Short-Term Debt to Total Capital		 28.40% 35.69% 51.07% 25.43% 31.12% 31.75% 22.99% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 3.05% 46.08% 14.08% 23.43% 36.78% 91.77% 467.70% -367.81% -199.11% -195.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 71.60% 61.26% 2.85% 60.49% 45.46% 31.48% -14.76% -367.70% 467.81% 299.11% 295.49%
Debt to EBITDA		 -0.67 -0.79 -1.14 -0.98 -0.64 -0.86 -0.88 -1.11 -4.65 -11.44 5.74
Net Debt to EBITDA		 1.87 1.85 0.24 1.87 0.75 0.56 0.90 3.11 4.26 3.30 -0.48
Long-Term Debt to EBITDA		 0.00 -0.06 -0.54 -0.35 -0.27 -0.46 -0.70 -1.11 -4.65 -11.44 5.74
Debt to NOPAT		 -0.94 -1.09 -1.58 -1.36 -0.90 -1.20 -1.22 -1.09 -2.23 -4.18 -176.88
Net Debt to NOPAT		 2.62 2.56 0.34 2.59 1.05 0.78 1.25 3.07 2.04 1.21 14.89
Long-Term Debt to NOPAT		 0.00 -0.09 -0.75 -0.49 -0.38 -0.64 -0.98 -1.09 -2.23 -4.18 -176.88
Altman Z-Score		 0.00 -0.42 -6.97 -2.48 -3.15 -6.15 -2.94 -0.51 -1.68 -3.01 -2.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.56 1.02 1.23 1.68 1.65 1.78 3.06 5.46 4.90 3.31 2.63
Quick Ratio		 1.44 0.93 1.17 1.61 1.57 1.72 2.92 5.18 4.50 2.97 2.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -38 -14 -49 -33 -66 -77 27 214 -86 -36 -42
Operating Cash Flow to CapEx		 -36,368.87% -256.07% -1,012.66% -13,019.94% -25,290.98% -26,117.78% -26,285.60% -5,960.46% -11,980.01% -4,388.42% -4,628.11%
Free Cash Flow to Firm to Interest Expense		 -7.55 -2.65 -7.62 -3.81 -9.55 -7.68 3.77 61.87 -0.87 -0.26 -0.43
Operating Cash Flow to Interest Expense		 -7.71 -2.52 -8.24 -4.80 -13.37 -9.00 -19.05 -41.13 -1.63 -0.69 -0.53
Operating Cash Flow Less CapEx to Interest Expense		 -7.73 -3.51 -9.05 -4.84 -13.42 -9.03 -19.12 -41.82 -1.65 -0.71 -0.54
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.15 0.37 0.25 0.19 0.13 0.30 0.07 0.34 0.48 0.62 0.89
Accounts Receivable Turnover		 2.35 6.13 3.51 3.38 3.97 3.69 1.16 8.26 6.77 6.16 6.63
Inventory Turnover		 0.00 1.19 2.18 0.00 0.00 0.00 0.00 0.63 0.30 0.16 0.67
Fixed Asset Turnover		 53.05 18.02 3.50 2.59 2.21 5.93 2.46 19.86 31.25 40.11 57.46
Accounts Payable Turnover		 0.00 0.23 0.34 0.22 0.00 0.34 0.09 0.31 0.30 0.25 0.75
Days Sales Outstanding (DSO)		 155.64 59.50 103.95 107.86 91.99 98.80 315.49 44.19 53.92 59.22 55.08
Days Inventory Outstanding (DIO)		 0.00 306.17 167.80 0.00 0.00 0.00 0.00 576.36 1,233.87 2,289.54 546.95
Days Payable Outstanding (DPO)		 1,281,697.50 1,621.69 1,078.63 1,694.92 0.00 1,065.66 3,850.28 1,174.45 1,200.83 1,435.60 483.98
Cash Conversion Cycle (CCC)		 -1,281,541.86 -1,256.02 -806.88 -1,587.06 91.99 -966.86 -3,534.79 -553.90 86.95 913.16 118.04
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.37 -16 -0.83 -8.39 -8.23 -1.35 -150 -489 -507 -543 -502
Invested Capital Turnover		 -2.61 -5.19 -3.09 -5.46 -2.48 -10.20 -0.23 -0.49 -0.54 -0.63 -0.86
Increase / (Decrease) in Invested Capital		 5.67 -14 15 -7.56 0.16 6.89 -149 -338 -18 -36 41
Enterprise Value (EV)		 0.00 686 455 379 815 327 1,163 2,110 1,928 1,139 1,531
Market Capitalization		 0.00 757 467 483 885 381 1,315 2,492 2,140 1,227 1,558
Book Value per Share		 $1.13 $0.65 $0.02 $0.85 $0.45 $0.35 ($0.11) ($0.59) ($1.58) ($2.22) ($2.30)
Tangible Book Value per Share		 $1.13 $0.65 $0.02 $0.85 $0.45 $0.35 ($0.11) ($0.59) ($1.58) ($2.22) ($2.30)
Total Capital		 106 78 55 138 108 122 130 29 -63 -152 -161
Total Debt		 30 30 54 55 59 83 150 136 232 303 315
Total Long-Term Debt		 0.00 2.38 25 20 25 45 120 136 232 303 315
Net Debt		 -84 -71 -11 -104 -69 -55 -153 -382 -212 -88 -27
Capital Expenditures (CapEx)		 0.11 5.12 5.28 0.32 0.37 0.34 0.51 2.39 1.35 2.17 1.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -24 -15 -32 -27 -27 -54 -49 -15 -45 -59
Debt-free Net Working Capital (DFNWC)		 62 29 41 86 79 111 248 462 411 346 262
Net Working Capital (NWC)		 32 1.54 13 51 45 72 218 462 411 346 262
Net Nonoperating Expense (NNE)		 13 15 21 26 35 39 60 60 143 154 87
Net Nonoperating Obligations (NNO)		 -78 -64 -2.41 -92 -57 -40 -131 -382 -212 -88 -27
Total Depreciation and Amortization (D&A)		 0.77 1.19 1.56 1.74 1.77 2.12 4.19 55 99 77 57
Debt-free, Cash-free Net Working Capital to Revenue		 -79.89% -49.39% -58.16% -126.69% -132.84% -55.67% -305.64% -30.88% -5.46% -13.52% -13.20%
Debt-free Net Working Capital to Revenue		 455.98% 60.80% 155.09% 340.57% 380.46% 226.46% 1,393.14% 294.22% 151.75% 104.40% 58.04%
Net Working Capital to Revenue		 235.52% 3.19% 47.91% 200.73% 217.28% 147.46% 1,224.71% 294.22% 151.75% 104.40% 58.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.68) $0.00 ($0.75) ($0.78) ($0.98) ($0.94) ($1.09) ($1,030.00) ($1.33) ($1.18) ($0.43)
Adjusted Weighted Average Basic Shares Outstanding		 72.32M 73.58M 73.96M 98.61M 110.18M 154.19M 177.18M 184.66M 185.91M 192.20M 206.70M
Adjusted Diluted Earnings per Share		 ($0.68) $0.00 ($0.75) ($0.78) ($0.98) ($0.94) ($1.09) ($1,030.00) ($1.33) ($1.18) ($0.43)
Adjusted Weighted Average Diluted Shares Outstanding		 72.32M 73.58M 73.70M 84.45M 103.19M 115.60M 167.27M 179.12M 185.91M 192.20M 206.70M
Adjusted Basic & Diluted Earnings per Share		 ($0.68) ($0.59) ($0.75) ($0.78) ($0.98) ($0.94) ($1.09) ($1,030.00) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.77M 73.58M 73.96M 98.61M 110.18M 154.19M 177.18M 184.66M 188.45M 206.15M 208.96M
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -28 -34 -40 -66 -70 -122 -124 -104 -73 -1.78
Normalized NOPAT Margin		 -235.45% -57.22% -129.11% -159.56% -319.34% -142.56% -686.78% -79.15% -38.37% -21.91% -0.40%
Pre Tax Income Margin		 -332.08% -89.15% -209.25% -261.18% -490.25% -222.99% -1,026.35% -115.68% -90.24% -68.26% -19.29%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -9.16 -7.59 -7.49 -6.70 -13.62 -9.99 -24.64 -51.42 -1.50 -0.76 -0.03
NOPAT to Interest Expense		 -6.41 -5.31 -5.25 -4.69 -9.53 -6.99 -17.25 -36.00 -1.05 -0.53 -0.02
EBIT Less CapEx to Interest Expense		 -9.18 -8.57 -8.31 -6.74 -13.68 -10.02 -24.71 -52.11 -1.51 -0.77 -0.04
NOPAT Less CapEx to Interest Expense		 -6.43 -6.29 -6.06 -4.73 -9.58 -7.03 -17.32 -36.69 -1.06 -0.54 -0.03
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for BioCryst Pharmaceuticals

This table displays calculated financial ratios and metrics derived from BioCryst Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 84.97% 68.68% 37.77% 25.88% 14.39% 17.42% 34.87% 32.54% 34.98% 40.83%
EBITDA Growth		 101.99% 91.03% 70.01% 103.52% 1,257.40% -751.35% 122.63% 4,162.10% 148.32% 127.03%
EBIT Growth		 60.87% 11.24% 43.12% 40.38% 31.67% 7.86% 49.01% 142.32% 164.52% 89.44%
NOPAT Growth		 60.87% 11.24% 43.12% 40.38% 31.67% 7.86% 49.01% 142.32% 164.52% 89.44%
Net Income Growth		 27.69% -302.39% 28.12% -27.98% 14.98% 13.71% 33.66% 83.17% 61.18% 56.59%
EPS Growth		 30.30% -280.00% 30.00% -25.00% 17.39% 18.42% 39.29% 85.00% 63.16% 58.06%
Operating Cash Flow Growth		 -39.39% 26.53% 38.93% 32.22% 38.67% 62.61% -12.99% 92.73% 141.44% 41.55%
Free Cash Flow Firm Growth		 173.87% -104.73% -99.26% -96.98% -93.97% 144.77% 37.26% -93.33% -58.32% -785.70%
Invested Capital Growth		 -200.35% -3.71% -4.69% -4.98% -5.62% -7.15% -2.67% 1.09% -0.45% 7.48%
Revenue Q/Q Growth		 15.71% 4.90% -13.54% 19.94% 5.15% 7.68% -0.69% 17.86% 7.09% 12.34%
EBITDA Q/Q Growth		 103.62% -605.76% -198.50% 106.44% 1,296.45% -417.21% 107.93% 1,112.76% -18.64% -65.47%
EBIT Q/Q Growth		 49.76% -165.47% 38.64% 27.14% 42.42% -257.94% 66.05% 160.47% -12.20% -158.61%
NOPAT Q/Q Growth		 49.76% -165.47% 38.64% 27.14% 42.42% -257.94% 66.05% 160.47% -12.20% -158.61%
Net Income Q/Q Growth		 27.76% -68.25% 25.45% -41.24% 52.01% -70.77% 42.69% 64.18% -10.72% -90.94%
EPS Q/Q Growth		 28.13% -65.22% 26.32% -42.86% 52.50% -63.16% 45.16% 64.71% -16.67% -85.71%
Operating Cash Flow Q/Q Growth		 -16.89% 26.49% -99.22% 60.40% -5.76% 55.18% -501.97% 97.45% 702.70% -163.23%
Free Cash Flow Firm Q/Q Growth		 -3.01% -104.68% 115.37% 332.47% 94.01% -65.28% -15.04% -78.98% 1,111.85% -671.19%
Invested Capital Q/Q Growth		 1.24% -6.60% 2.75% -2.54% 0.64% -8.14% 6.33% 1.21% -0.91% 0.40%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 95.33% 97.00% 98.65% 98.92% 98.73% 98.33% 98.64% 98.45% 97.26% 95.37%
EBITDA Margin		 0.80% -3.87% -13.35% 0.72% 9.51% -28.03% 2.24% 23.04% 17.50% 5.38%
Operating Margin		 -23.01% -58.22% -41.31% -25.10% -13.74% -45.68% -15.62% 8.01% 6.57% -3.43%
EBIT Margin		 -23.01% -58.22% -41.31% -25.10% -13.74% -45.68% -15.62% 8.01% 6.57% -3.43%
Profit (Net Income) Margin		 -56.08% -89.94% -77.54% -91.31% -41.67% -66.09% -38.14% -11.59% -11.99% -20.37%
Tax Burden Percent		 103.71% 100.11% 101.27% 100.99% 100.92% 97.73% 101.04% 101.38% 104.36% 103.09%
Interest Burden Percent		 235.01% 154.32% 185.33% 360.27% 300.47% 148.02% 241.68% -142.70% -174.82% 576.55%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 99.23% 123.07% 91.88% 80.65% 72.32% 60.40% 51.86% 33.77% 28.15% 19.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -13.31% -27.71% -23.07% -14.79% -8.07% -28.38% -11.36% 6.11% 5.35% -3.07%
Return on Assets (ROA)		 -32.44% -42.80% -43.30% -53.83% -24.47% -41.06% -27.73% -8.84% -9.75% -18.23%
Return on Common Equity (ROCE)		 99.23% 123.07% 91.88% 80.65% 72.32% 60.40% 51.86% 33.77% 28.15% 19.08%
Return on Equity Simple (ROE_SIMPLE)		 79.68% 0.00% 68.92% 62.44% 57.51% 0.00% 43.81% 30.68% 26.42% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -32 -20 -14 -8.34 -30 -10 6.13 5.38 -3.16
NOPAT Margin		 -16.10% -40.75% -28.92% -17.57% -9.62% -31.98% -10.93% 5.61% 4.60% -2.40%
Net Nonoperating Expense Percent (NNEP)		 -24.84% -13.17% -14.20% -31.61% -17.16% -21.26% -25.96% -26.67% -30.55% -41.45%
Return On Investment Capital (ROIC_SIMPLE)		 - 51.48% - - - 19.61% - - - 1.96%
Cost of Revenue to Revenue		 4.67% 3.00% 1.35% 1.08% 1.27% 1.67% 1.36% 1.55% 2.74% 4.63%
SG&A Expenses to Revenue		 48.69% 63.05% 69.60% 61.82% 58.39% 68.93% 64.00% 55.99% 55.59% 61.18%
R&D to Revenue		 69.55% 92.03% 70.35% 62.12% 54.04% 75.00% 50.12% 34.41% 35.09% 37.59%
Operating Expenses to Revenue		 118.33% 155.22% 139.96% 124.01% 112.48% 144.02% 114.25% 90.43% 90.69% 98.79%
Earnings before Interest and Taxes (EBIT)		 -17 -46 -28 -21 -12 -43 -14 8.76 7.69 -4.51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.61 -3.08 -9.18 0.59 8.25 -26 2.08 25 20 7.08
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 9.83 7.90 5.43 4.34 4.22 3.70 2.93 3.34 3.81 3.46
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 8.85 7.12 4.86 3.96 3.94 3.44 2.84 3.27 3.72 3.40
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 133.95 71.19 27.92
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 10.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 -0.95 -0.79 -0.73 -0.77 -0.75 -0.67 -0.65 -0.66 -0.67 -0.66
Long-Term Debt to Equity		 -0.95 -0.79 -0.73 -0.77 -0.75 -0.67 -0.65 -0.66 -0.67 -0.66
Financial Leverage		 0.63 1.48 0.96 0.64 0.50 0.40 0.24 0.16 0.14 0.12
Leverage Ratio		 -2.12 -2.83 -2.11 -1.73 -1.65 -1.42 -1.22 -1.16 -1.15 -1.08
Compound Leverage Factor		 -4.97 -4.37 -3.90 -6.23 -4.97 -2.11 -2.94 1.65 2.02 -6.24
Debt to Total Capital		 -1,792.23% -367.81% -265.45% -333.18% -298.92% -199.11% -183.97% -193.98% -203.81% -195.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -1,792.23% -367.81% -265.45% -333.18% -298.92% -199.11% -183.97% -193.98% -203.81% -195.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 1,892.23% 467.81% 365.45% 433.18% 398.92% 299.11% 283.97% 293.98% 303.81% 295.49%
Debt to EBITDA		 -2.84 -4.65 -8.39 -27.04 -90.31 -11.44 -20.22 33.60 14.57 5.74
Net Debt to EBITDA		 2.87 4.26 5.79 10.56 26.75 3.30 1.96 -2.60 -1.66 -0.48
Long-Term Debt to EBITDA		 -2.84 -4.65 -8.39 -27.04 -90.31 -11.44 -20.22 33.60 14.57 5.74
Debt to NOPAT		 -2.13 -2.23 -2.68 -3.78 -4.10 -4.18 -4.91 -7.43 -11.03 -176.88
Net Debt to NOPAT		 2.16 2.04 1.85 1.48 1.21 1.21 0.48 0.58 1.26 14.89
Long-Term Debt to NOPAT		 -2.13 -2.23 -2.68 -3.78 -4.10 -4.18 -4.91 -7.43 -11.03 -176.88
Altman Z-Score		 -0.47 -1.07 -1.68 -1.92 -2.00 -2.62 -2.98 -2.85 -2.43 -2.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 6.23 4.90 5.76 5.47 5.54 3.31 3.73 2.82 2.78 2.63
Quick Ratio		 5.75 4.50 5.25 5.01 4.97 2.97 3.31 2.64 2.62 2.49
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 305 -14 2.19 9.48 18 6.39 3.01 0.63 7.67 -44
Operating Cash Flow to CapEx		 -18,539.43% -4,534.03% -29,695.00% -4,028.69% -2,015.91% -1,609.75% -22,844.26% -882.58% 13,974.58% -772.30%
Free Cash Flow to Firm to Interest Expense		 12.31 -0.54 0.08 0.16 0.67 0.26 0.12 0.03 0.31 -1.79
Operating Cash Flow to Interest Expense		 -1.31 -0.90 -1.73 -0.32 -0.73 -0.36 -2.19 -0.06 0.33 -0.21
Operating Cash Flow Less CapEx to Interest Expense		 -1.32 -0.92 -1.74 -0.33 -0.76 -0.39 -2.20 -0.06 0.33 -0.24
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.58 0.48 0.56 0.59 0.59 0.62 0.73 0.76 0.81 0.89
Accounts Receivable Turnover		 6.93 6.77 6.81 6.18 6.60 6.16 6.51 6.05 6.54 6.63
Inventory Turnover		 0.22 0.30 0.33 0.31 0.19 0.16 0.17 0.36 0.42 0.67
Fixed Asset Turnover		 29.27 31.25 33.73 35.78 36.37 40.11 43.86 47.48 50.25 57.46
Accounts Payable Turnover		 0.31 0.30 0.71 0.60 0.55 0.25 0.53 0.52 0.64 0.75
Days Sales Outstanding (DSO)		 52.68 53.92 53.58 59.01 55.32 59.22 56.09 60.36 55.78 55.08
Days Inventory Outstanding (DIO)		 1,671.05 1,233.87 1,120.49 1,186.94 1,948.08 2,289.54 2,169.80 1,022.36 877.85 546.95
Days Payable Outstanding (DPO)		 1,163.06 1,200.83 517.34 610.13 659.88 1,435.60 688.46 703.86 567.63 483.98
Cash Conversion Cycle (CCC)		 560.66 86.95 656.74 635.83 1,343.51 913.16 1,537.43 378.86 366.00 118.04
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -475 -507 -493 -505 -502 -543 -506 -500 -504 -502
Invested Capital Turnover		 -0.75 -0.54 -0.60 -0.62 -0.65 -0.63 -0.71 -0.76 -0.82 -0.86
Increase / (Decrease) in Invested Capital		 -317 -18 -22 -24 -27 -36 -13 5.50 -2.28 41
Enterprise Value (EV)		 2,110 1,928 1,407 1,213 1,250 1,139 1,011 1,251 1,536 1,531
Market Capitalization		 2,343 2,140 1,572 1,330 1,342 1,227 1,040 1,275 1,572 1,558
Book Value per Share		 ($1.31) ($1.58) ($1.74) ($2.06) ($2.17) ($2.22) ($2.31) ($2.30) ($2.26) ($2.30)
Tangible Book Value per Share		 ($1.31) ($1.58) ($1.74) ($2.06) ($2.17) ($2.22) ($2.31) ($2.30) ($2.26) ($2.30)
Total Capital		 -13 -63 -90 -90 -103 -152 -168 -162 -154 -161
Total Debt		 230 232 238 299 308 303 308 314 314 315
Total Long-Term Debt		 230 232 238 299 308 303 308 314 314 315
Net Debt		 -233 -212 -165 -117 -91 -88 -30 -24 -36 -27
Capital Expenditures (CapEx)		 0.18 0.53 0.16 0.47 0.99 0.55 0.24 0.16 0.06 0.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.94 -15 6.11 5.31 13 -45 -11 -39 -57 -59
Debt-free Net Working Capital (DFNWC)		 427 411 406 418 412 346 327 234 274 262
Net Working Capital (NWC)		 427 411 406 418 412 346 327 234 274 262
Net Nonoperating Expense (NNE)		 30 39 33 61 28 32 25 19 19 24
Net Nonoperating Obligations (NNO)		 -233 -212 -165 -117 -91 -88 -30 -24 -36 -27
Total Depreciation and Amortization (D&A)		 18 43 19 21 20 16 17 16 13 12
Debt-free, Cash-free Net Working Capital to Revenue		 -0.39% -5.46% 2.11% 1.73% 3.95% -13.52% -3.14% -10.32% -13.88% -13.20%
Debt-free Net Working Capital to Revenue		 179.23% 151.75% 140.06% 136.17% 129.65% 104.40% 92.06% 61.32% 66.30% 58.04%
Net Working Capital to Revenue		 179.23% 151.75% 140.06% 136.17% 129.65% 104.40% 92.06% 61.32% 66.30% 58.04%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.23) ($0.38) ($0.28) ($0.40) ($0.19) ($0.31) ($0.17) ($0.06) ($0.07) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 186.18M 185.91M 188.51M 189.12M 189.64M 192.20M 206.06M 206.43M 206.91M 206.70M
Adjusted Diluted Earnings per Share		 ($0.23) ($0.38) ($0.28) ($0.40) ($0.19) ($0.31) ($0.17) ($0.06) ($0.07) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding		 186.18M 185.91M 188.51M 189.12M 189.64M 192.20M 206.06M 206.43M 206.91M 206.70M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 186.42M 188.45M 188.93M 189.49M 204.81M 206.15M 206.38M 206.89M 207.13M 208.96M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -32 -20 -14 -8.34 -30 -10 6.13 5.38 -3.16
Normalized NOPAT Margin		 -16.10% -40.75% -28.92% -17.57% -9.62% -31.98% -10.93% 5.61% 4.60% -2.40%
Pre Tax Income Margin		 -54.07% -89.84% -76.57% -90.42% -41.29% -67.62% -37.75% -11.43% -11.48% -19.76%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -0.70 -1.75 -1.04 -0.36 -0.44 -1.74 -0.59 0.35 0.31 -0.18
NOPAT to Interest Expense		 -0.49 -1.23 -0.73 -0.25 -0.31 -1.22 -0.41 0.25 0.22 -0.13
EBIT Less CapEx to Interest Expense		 -0.71 -1.77 -1.04 -0.37 -0.47 -1.76 -0.60 0.35 0.31 -0.21
NOPAT Less CapEx to Interest Expense		 -0.50 -1.25 -0.73 -0.26 -0.34 -1.24 -0.42 0.24 0.21 -0.16
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About BioCryst Pharmaceuticals' Financials

When does BioCryst Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, BioCryst Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has BioCryst Pharmaceuticals' net income changed over the last 10 years?

BioCryst Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$88.88 million in 2024, rising from -$45.19 million in 2014. The previous period was -$226.54 million in 2023. Find out what analysts predict for BioCryst Pharmaceuticals in the coming months.

What is BioCryst Pharmaceuticals's operating income?
BioCryst Pharmaceuticals's total operating income in 2024 was -$2.54 million, based on the following breakdown:
  • Total Gross Profit: $438.44 million
  • Total Operating Expenses: $440.99 million
How has BioCryst Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, BioCryst Pharmaceuticals' total revenue changed from $13.61 million in 2014 to $450.71 million in 2024, a change of 3,212.1%.

How much debt does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals' total liabilities were at $966.35 million at the end of 2024, a 0.6% decrease from 2023, and a 1,478.0% increase since 2014.

How much cash does BioCryst Pharmaceuticals have?

In the past 10 years, BioCryst Pharmaceuticals' cash and equivalents has ranged from $22.10 million in 2016 to $504.39 million in 2021, and is currently $104.71 million as of their latest financial filing in 2024.

How has BioCryst Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, BioCryst Pharmaceuticals' book value per share changed from 1.13 in 2014 to -2.30 in 2024, a change of -302.9%.


Related Companies

This page (NASDAQ:BCRX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...
Colonial Metals | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...
Weiss Ratings | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored